OPKO Health, Inc. — 2014 Form 10-K
Business context and reporting period. OPKO is a multinational biopharmaceutical and diagnostics company with pharmaceutical operations, a clinical laboratory, and drug and diagnostic programs at varying development stages. This filing covers the fiscal year ended December 31, 2014; it is an annual report, not a standalone fourth-quarter filing. Financial statements were audited by Ernst & Young, which issued an unqualified opinion.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $91.1 million | $96.5 million |
| Gross profit and gross margin | $43.1 million; 47.3% | $47.7 million; 49.4% |
| Operating loss | $145.8 million | $79.6 million |
| Net loss attributable to common shareholders | $171.7 million; $0.41 per share | $114.8 million; $0.32 per share |
| Cash used in operating activities | $90.4 million | $55.7 million |
| Cash and cash equivalents at year-end | $96.9 million | $185.8 million |
| Working capital | $59.8 million | $150.9 million |
| Total assets / shareholders’ equity | $1.268 billion / $835.7 million | $1.392 billion / $873.0 million |
Cash used in investing activities was $5.7 million; capital expenditures were $4.7 million. Cash provided by financing activities was $7.3 million. At year-end, OPKO reported $87.6 million principal outstanding on its 3% convertible senior notes due 2033, $7.7 million outstanding on short-term lines of credit, and $3.0 million in mortgages and other debt. The balance-sheet carrying amount for the 2033 notes was $131.5 million, including the accounting effect of embedded derivatives. Total contractual obligations were $136.0 million, including $14.7 million in open purchase orders.
Changes versus the prior year
- Revenue fell 5.6%. The main comparison was against $12.5 million of non-cash intellectual-property revenue recognized in 2013; higher pharmaceutical sales and a $5.0 million TESARO milestone partly offset the decline.
- Research and development expense rose to $83.6 million from $53.9 million, reflecting OPKO Biologics development and manufacturing costs and Rayaldee trials.
- Operating loss widened to $145.8 million from $79.6 million. Net loss attributable to common shareholders increased to $171.7 million from $114.8 million.
- Operating cash use increased by $34.7 million, while year-end cash declined by $88.9 million. The 2013 cash balance included proceeds from the issuance of the convertible notes.
- Contingent-consideration expense increased to $24.4 million from $6.9 million, primarily after positive Rayaldee Phase 3 results raised estimated milestone-payment obligations.
- The company corrected prior cash-flow classifications and a 2013 presentation between derivative fair-value expense and conversion loss. It stated these corrections did not change net loss, earnings per share, total cash flows, or taxes.
Outlook, developments, and risks
- Pfizer agreement: The exclusive worldwide hGH-CTP agreement was signed in December 2014 and closed in January 2015. OPKO received $295 million in non-refundable upfront payments after year-end and may receive up to $275 million in regulatory milestones. OPKO funds specified core-indication development up to an agreed cap; Pfizer funds commercialization, manufacturing activities under the development plan, additional-indication development, and post-marketing studies. The filing does not provide a numerical earnings or revenue forecast.
- Pipeline: OPKO reported successful top-line results from two Rayaldee Phase 3 trials and planned an FDA NDA submission for the first quarter of 2015. hGH-CTP was in a global Phase 3 adult trial and Phase 2 pediatric trial. Alpharen remained a development program. The 4Kscore began U.S. sales in March 2014 and European sales in September; Mexico launch followed in January 2015.
- Liquidity outlook: Management said cash, the Pfizer proceeds, and available credit were expected to fund operations and debt service beyond the next 12 months, while cautioning that assumptions could change and further funding might be needed. OPKO expected to pay $25.6 million to Israel’s Office of the Chief Scientist in the first quarter of 2015 in connection with prior grants and the hGH-CTP out-license.
- Continuing losses and asset concentration: Management expected substantial operating losses for the foreseeable future. Goodwill and intangible assets totaled about $1.1 billion, approximately 85% of assets, including $793.2 million of in-process research and development; impairment could materially affect reported results.
- Legal and regulatory matters: The U.S. Attorney’s Office for the Middle District of Tennessee issued a Civil Investigative Demand concerning alleged false claims tied to government healthcare beneficiaries. OPKO said it would cooperate; outcome and any loss range were not estimable. OPKO Lab also continued to appeal alleged Medicare overpayments following an audit. PAMA reimbursement changes and proposed FDA oversight of laboratory-developed tests were identified as business risks.
- Accounting and controls: Fair-value changes in embedded derivatives on the convertible notes materially affect reported results. Management and the auditor concluded internal control over financial reporting was effective at year-end 2014, following remediation of a prior Chile-subsidiary material weakness; SciVac’s controls were excluded from their assessment.
Investor verification priorities
- Confirm the receipt and accounting treatment of the $295 million Pfizer upfront payment, the development-cost cap, milestone conditions, and the $25.6 million OCS payment.
- Track operating cash use, cash runway, liquidity, and financing needs against management’s stated expectation of funding beyond 12 months.
- Review Rayaldee’s NDA progress and subsequent regulatory decisions, plus clinical progress for hGH-CTP and Alpharen.
- Assess the Tennessee investigation and Medicare audit appeals, including any later disclosures of outcomes or financial exposure.
- Monitor potential impairment of the large IPR&D and other intangible-asset balances, and volatility from the notes’ embedded derivatives.
- Check 4Kscore adoption, reimbursement, and revenue contribution; 2014 diagnostics product revenue was not separately reported as product revenue in the filing.